CARDIOXYL PHARMACEUTICALS
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
CARDIOXYL PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.cardioxyl.com
Total Employee:
10001+
Status:
Active
Contact:
+119198698586
Email Addresses:
[email protected]
Total Funding:
66.5 M USD
Technology used in webpage:
SPF Google Font API Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS GStatic Google Static Content Google Maps API Level 3 Communications
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
The Aurora Funds
The Aurora Funds investment in Series B - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series B - Cardioxyl Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Cardioxyl Pharmaceuticals
OrbiMed
OrbiMed investment in Series B - Cardioxyl Pharmaceuticals
The Aurora Funds
The Aurora Funds investment in Venture Round - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Venture Round - Cardioxyl Pharmaceuticals
The Aurora Funds
The Aurora Funds investment in Series A - Cardioxyl Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series A - Cardioxyl Pharmaceuticals
Official Site Inspections
http://www.cardioxyl.com
- Host name: 165.89.235.20
- IP address: 165.89.235.20
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Cardioxyl Pharmaceuticals"
Cardioxyl Pharmaceuticals - Crunchbase Company …
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, …See details»
Cardioxyl Pharmaceuticals - Products, Competitors, Financials ...
Headquarters Location. 40 York Road, Suite 501 . Towson, Maryland, 21204, United States (877)792-5089See details»
Johns Hopkins-Derived Drug Could Transform Heart Failure …
Oct 31, 2016 In 2015, two Johns Hopkins researchers and their business partners sold a company they co-founded for $300 million to Bristol-Myers Squibb. The company, Cardioxyl …See details»
Cardioxyl Pharmaceuticals - News, Articles etc. - European ...
Nov 3, 2015 news Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals. 3 November 2015 | By Victoria White The acquisition will give Bristol-Myers Squibb full rights to Cardioxyl’s lead …See details»
Cardioxyl begins Phase I study of CXL-1427 for heart failure …
Feb 26, 2014 US-based Cardioxyl Pharmaceuticals has started dosing the first cohort of patients in a Phase I clinical study of CXL-1427, a new nitroxyl (HNO) prodrug optimised for clinical …See details»
Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
Nov 2, 2015 Gains full rights to Cardioxyl’s novel nitroxyl (HNO) donor in Phase 2 development for acute decompensated heart failure Strengthens Bristol-Myers Squibb’s pipeline and …See details»
Bristol-Myers to Acquire Cardioxyl, Focus on Heart Failure
Nov 3, 2015 Bristol-Myers Squibb Company BMY announced yet another deal to strengthen its heart failure pipeline. The company has signed a definitive agreement to acquire Cardioxyl …See details»
Cardioxyl Pharmaceuticals - Funding, Financials, Valuation
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Bristol-Myers bets $2B on Cardioxyl's heart failure therapy
Nov 2, 2015 Bristol-Myers Squibb is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.See details»
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Bristol-Myers Squibb (BMS) has agreed to buy US heart drug specialist Cardioxyl Pharmaceuticals for $300 million (£195 million) up front, plus up to $1.8 billion contingent on …See details»
Bristol-Myers to Buy Heart-Drug Maker Cardioxyl - WSJ
Nov 2, 2015 Bristol-Myers Squibb Co. plans to buy Cardioxyl Pharmaceuticals, giving Bristol the rights to Cardioxyl’s lead asset, an experimental drug called CXL-1427.See details»
Home - Cardiol Therapeutics
Key International Research and Clinical Collaborators. We collaborate with world-class researchers and clinicians at international centers of excellence and leverage their expertise in …See details»
BMS to Buy Cardioxyl for Up to $2.075B - genengnews.com
Nov 2, 2015 Bristol-Myers Squibb (BMS) will acquire cardiovascular disease drug developer Cardioxyl for up to $2.075 billion, in a deal that strengthens the buyer’s pipeline in one of its …See details»
Bristol-Myers to buy US biotechnology firm Cardioxyl for $2.07bn
Nov 3, 2015 Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical …See details»
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc.
Nov 2, 2015 Bristol-Myers Squibb Company (NYSE:BMY) and Cardioxyl Pharmaceuticals, Inc. announced today that the companies have signed a definitive agreement under which Bristol …See details»
Cardioxyl Pharmaceuticals Announces Positive Results from First ...
CHAPEL HILL, N.C., Aug. 2 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of …See details»
Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study …
CHAPEL HILL, N.C., Aug. 26 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular …See details»
Cardioxyl Pharmaceuticals Successfully Completes First Clinical …
CHAPEL HILL, N.C., July 28, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential …See details»
Cardioxyl Pharmaceuticals completes first clinical trial for heart ...
Jul 29, 2014 Cardioxyl Pharmaceuticals has announced the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart …See details»
Cardioxil ¿Para qué Sirve?, Precio Farmacia del Ahorro, similares ...
Jul 17, 2023 Contraindicaciones y efectos secundarios. De acuerdo con la información proporcionada por Cardioxil, existen ciertas contraindicaciones y efectos secundarios …See details»